For gastrointestinal symptoms commonly associated with GLP-1 therapy, research on specific strains (though not in GLP-1 users specifically) includes: Lactobacillus rhamnosus GG (ATCC 53103) has evidence for diarrhoea management Bifidobacterium lactis BB-12 and Bifidobacterium longum BB536 have been studied for constipation relief Lactobacillus plantarum 299v has some evidence for bloating and abdominal discomfort Colony-forming units (CFUs) indicate the number of viable bacteria per dose
Clinical trials demonstrate consistent weekly schedulingtypically on the same dayproduces stable GLP-1 receptor activation and predictable appetite suppression
Grech O, Mitchell JL, Lyons HS, Yiangou A, Thaller M, Tsermoulas G, Brock K, Mollan SP, Sinclair AJ (2024) Effect of glucagon like peptide-1 receptor agonist exenatide, used as an intracranial pressure lowering agent, on cognition in idiopathic intracranial hypertension
Covalent modification of DNA regulates memory formation